Increment de Ritis ratio as a marker factor for worsening Coronavirus disease 2019 patients
Abstract
Introduction: the coronavirus (Covid-19), identified as the betacoronavirus genus, not only appears in the respiratory tract but can also appear in other organs such as the liver. The ratio of aspartate aminotransferase (AST) to alanine aminotransfarese (ALT) activity, known as the de Ritis ratio, can be used as a marker of liver dysfunction.
Objectives: the study aimed to evaluate the increment de Ritis ratio as a predictor of exacerbation of COVID-19.
Methods & Materials: This study was a retrospective cross-sectional study from April to November 2022. Ramelan Naval Hospital Center Surabaya, Dr Mohammad Soewandhie Surabaya Hospital, and Bhakti Rahayu Hospital Surabaya collected samples from 187 people with confirmed COVID-19.
Results: The median age of COVID-19 patients was 45.97 years, the length of hospital stay was 8,67 days, and the de Ritis ratio was 1,57. Spearman’s test for increment de Ritis ratio with the length of hospitalization for COVID-10 patients with r 0.11. Conversely, an increment of ratio de Ritis in discharge patients was found with r-0.52. Conclusion: Higher rates of de Ritis Ratio lead to longer hospital stays and higher mortality for COVID-19 patients
Keywords
References
Anirvan, P. et al. (2020) “Liver injury in COVID-19: The hepatic aspect of the respiratory syndrome — what we know so far,” World Journal of Hepatology, 12(12), hal. 1182–1197.
Cichoż-Lach, H. dan Michalak, A. (2021) “Liver injury in the era of COVID-19,” World Journal of Gastroenterology, 27(5), hal. 377–390.
Drácz, B. (2022) “The elevated De Ritis ratio on admission is independently associated with mortality in COVID- 19 patients,” Viruses, 14(11), hal. 1–19.
Fu, Y. et al. (2022) “A linear relationship between De Ritis ratio and mortality in hospitalized patients with COVID-19: A secondary analysis based on a large retrospective cohort study,” iLIVER, (June). Guan, W. et al. (2019) “Disease 2019 in China,” hal. 1–13.
Lippi, G. et al. (2020) “Current laboratory diagnostics of coronavirus disease 2019 (COVID-19),” Acta Biomedica, 91(2), hal. 137–145.
Łykowska-Szuber, L. et al. (2021) “Liver injury in patients with coronavirus disease 2019 (COVID-19)—A narrative review,” Journal of Clinical Medicine, 10(21).
Machhi, J. et al. (2020) “The Natural History, Pathobiology, and Clinical Manifestations of SARS-CoV-2 Infections,” Journal of Neuroimmune Pharmacology, 15(3), hal. 359–386.
Marjot, T. et al. (2021) “COVID-19 and liver disease: mechanistic and clinical perspectives,” Nature Reviews Gastroenterology and Hepatology, 18(5), hal. 348–364.
Nardo, A. D. et al. (2021) “Pathophysiological mechanisms of liver injury in COVID-19,” Liver International, 41(1), hal. 20–32.
Pranata, R. et al. (2021) “Elevated De Ritis Ratio Is Associated With Poor Prognosis in COVID-19: A Systematic Review and Meta-Analysis,” Frontiers in Medicine, 8(December), hal. 1–9.
Qin, C. et al. (2020) “High aspartate aminotransferase to alanine aminotransferase ratio on admission as risk factor for poor prognosis in COVID ‑ 19 patients,” Scientific Reports, hal. 1–10.
Yang, R. X., Zheng, R. D. dan Fan, J. G. (2020) “Etiology and management of liver injury in patients with COVID-19,” World Journal of Gastroenterology, 26(32), hal. 4753–4762.
Yazar, H., Kayacan, Y. dan Ozdin, M. (2020) “De Ritis ratio and biochemical parameters in COVID-19 patients,” Archives of Physiology and Biochemistry, 0(0), hal. 1–5.
Zhao, J. N., Fan, Y. dan Wu, S. D. (2020) “Liver injury in COVID-19: A minireview,” World Journal of Clinical Cases, 8(19), hal. 4303–4310.
Zinellu, A. et al. (2021) “The De Ritis ratio as prognostic biomarker of in-hospital mortality in COVID-19 patients,” European Journal of Clinical Investigation, 51(1),
DOI: 10.24815/jks.v24i1.33814
Refbacks
- There are currently no refbacks.